Kymera Therapeutics to Participate in Upcoming February Investor Conferences
Kymera Therapeutics (NASDAQ: KYMR) announced participation in two investor fireside chats in February 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kymera Therapeutics (NASDAQ: KYMR) announced participation in two investor fireside chats in February 2026. The company will present at Guggenheim Emerging Outlook: Biotech Summit on Feb 11, 2026 at 9:00 a.m. ET and at Oppenheimer Virtual Healthcare Life Sciences on Feb 26, 2026 at 2:00 p.m. ET.
Live webcasts and archived replays will be available in the Investors section of the company website under “News and Events.”
Details
News Market Reaction – KYMR
On Feb 4, the day this news came out, KYMR closed 0.62% above the previous close.
Data tracked by StockTitan Argus for the Feb 4 session.
Key Figures
- Investor conferences
- 2 events
- February 2026 conferences (Guggenheim, Oppenheimer)
- Guggenheim presentation time
- 9:00 a.m. ET
- February 11, 2026 Guggenheim Emerging Outlook: Biotech Summit
- Oppenheimer presentation time
- 2:00 p.m. ET
- February 26, 2026 Oppenheimer Virtual 36th Annual Healthcare Life Sciences Conference
Historical Context
-
First patient dosed in BREADTH Phase 2b asthma trial for KT-621.
-
Outlined 2026 objectives and reported ~$1.6B cash runway into 2029.
-
Announcement of presentation at 44th Annual J.P. Morgan Healthcare Conference.
-
Closing of upsized public offering with ~$692.3M in gross proceeds.
-
FDA Fast Track designation for KT-621 in atopic dermatitis.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
fireside chats financial
webcasts technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:
- Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY on February 11 at 9:00 a.m. ET; and
- Oppenheimer Virtual 36th Annual Healthcare Life Sciences Conference on February 26 at 2:00 p.m. ET.
Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.